Jessica A. Hellyer

Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer

Melinda L. Telli, Jessica A. Hellyer, William Audeh et al. · Breast Cancer Research and Treatment · 2017 · 128 citations

Homologous Recombination Deficiency, Breast Oncology, Medicine +7

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Jacqueline V. Aredo, Isa Mambetsariev, Jessica A. Hellyer et al. · Journal of Thoracic Oncology · 2021 · 126 citations · Full text

Medicine, Cancer Treatment, Oncology +3

Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response <i>In Vivo</i>

Giorgia Foggetti, Chuan Li, Hongchen Cai et al. · Cancer Discovery · 2021 · 118 citations · Full text

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Ferdinandos Skoulidis, Haniel A. Araújo, Minh Truong et al. · Nature · 2024 · 117 citations · Full text

Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non–Small Cell Lung Cancer

Youngtae Jeong, Jessica A. Hellyer, Henning Stehr et al. · Clinical Cancer Research · 2019 · 115 citations · Full text